La Jolla Pharmaceutical Company (LJPC) financial statements (2021 and earlier)

Company profile

Business Address 4550 TOWNE CENTRE COURT
SAN DIEGO, CA 92121
State of Incorp. CA
Fiscal Year End December 31
SIC 2836 - Biological Products, Except Diagnostic Substances (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
12/31/2013
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments881739166126499
Cash and cash equivalents881739166126499
Receivables31     
Inventory, net of allowances, customer advances and progress billings22    
Inventory22     
Other undisclosed current assets4532120
Total current assets:971819467128509
Noncurrent Assets
Property, plant and equipment1822253200
Restricted cash and investments111    
Other undisclosed noncurrent assets15  00  
Total noncurrent assets:3523253200
TOTAL ASSETS:13220412071129519
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities22291710521
Accounts payable49117311
Accrued liabilities91311110
Employee-related liabilities8852100
Deferred rent credit 1
Deferred revenue and credits1    
Other undisclosed current liabilities3      
Total current liabilities:25301910521
Noncurrent Liabilities
Liabilities, other than long-term debt131413    
Deferred revenue and credits13    
Deferred rent credit 14
Other liabilities13      
Other undisclosed noncurrent liabilities151124     
Total noncurrent liabilities:16413813    
Total liabilities:1881683110521
Stockholders' equity
Stockholders' equity attributable to parent, including:(56)368861125488
Common stock0000000
Additional paid in capital977950803661646528463
Accumulated deficit(1,037)(921)(722)(607)(529)(487)(465)
Other undisclosed stockholders' equity attributable to parent47777710
Total stockholders' equity:(56)368861125488
TOTAL LIABILITIES AND EQUITY:13220412071129519

Income statement (P&L) ($ in millions)

12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
12/31/2013
Revenues2310 11  
Revenue, net 11  
Cost of revenue
(Cost of Goods and Services Sold)
(2)(2)(2)(1)(1)  
Gross profit:218(2)00  
Operating expenses(130)(202)(115)(79)(43)(21)(18)
Other undisclosed operating income  211  
Operating loss:(110)(194)(115)(78)(42)(21)(18)
Nonoperating income (expense)
(Other Nonoperating Income (Expense))
 (5)10000
Interest and debt expense(11)(7)     
Net loss:(121)(207)(115)(78)(42)(21)(18)
Other undisclosed net income attributable to parent47     
Net loss attributable to parent:(117)(199)(115)(78)(42)(21)(18)
Preferred stock dividends and other adjustments      (1)
Net loss available to common stockholders, diluted:(117)(199)(115)(78)(42)(21)(19)

Comprehensive Income ($ in millions)

12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
12/31/2013
Net loss:(121)(207)(115)(78)(42)(21)(18)
Other undisclosed comprehensive income     43 
Comprehensive income (loss), net of tax, attributable to parent:(121)(207)(115)(78)(42)21(18)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: